TY - CHAP
T1 - Endothelial Cells (ECs) Metabolism
T2 - A Valuable Piece to Disentangle Cancer Biology
AU - Lopes-Coelho, Filipa
AU - Martins, Filipa
AU - Serpa, Jacinta
N1 - Funding Information:
The authors acknowledge iNOVA-4Health – UID/Multi/04462/2013, a program financially supported by Fundação para a Ciência e Tecnologia/ Ministério da Educação e Ciência, through national funds and co-funded by FEDER under the PT2020 Partnership Agreement.
Publisher Copyright:
© 2020, Springer Nature Switzerland AG.
PY - 2020
Y1 - 2020
N2 - Effective therapies to fight cancer should not be focused specifically on cancer cells, but it should consider the various components of the TME. Non-cancerous cells cooperate with cancer cells by sharing signaling and organic molecules, accounting for cancer progression. Most of the anti-angiogenic therapy clinically approved for the treatment of human diseases relies on targeting vascular endothelial growth factor (VEGF) signaling pathway. Unexpectedly and unfortunately, the results of anti-angiogenic therapies in the treatment of human diseases are not so effective, showing an insufficient efficacy and resistance. This chapter will give some insights on showing that targeting endothelial cell metabolism is a missing piece to revolutionize cancer therapy. Only recently endothelial cell (EC) metabolism has been granted as an important inducer of angiogenesis. Metabolic studies in EC demonstrated that targeting EC metabolism can be an alternative to overcome the failure of anti-angiogenic therapies. Hence, it is urgent to increase the knowledge on how ECs alter their metabolism during human diseases, in order to open new therapeutic perspectives in the treatment of pathophysiological angiogenesis, as in cancer.
AB - Effective therapies to fight cancer should not be focused specifically on cancer cells, but it should consider the various components of the TME. Non-cancerous cells cooperate with cancer cells by sharing signaling and organic molecules, accounting for cancer progression. Most of the anti-angiogenic therapy clinically approved for the treatment of human diseases relies on targeting vascular endothelial growth factor (VEGF) signaling pathway. Unexpectedly and unfortunately, the results of anti-angiogenic therapies in the treatment of human diseases are not so effective, showing an insufficient efficacy and resistance. This chapter will give some insights on showing that targeting endothelial cell metabolism is a missing piece to revolutionize cancer therapy. Only recently endothelial cell (EC) metabolism has been granted as an important inducer of angiogenesis. Metabolic studies in EC demonstrated that targeting EC metabolism can be an alternative to overcome the failure of anti-angiogenic therapies. Hence, it is urgent to increase the knowledge on how ECs alter their metabolism during human diseases, in order to open new therapeutic perspectives in the treatment of pathophysiological angiogenesis, as in cancer.
KW - Angiogenesis
KW - Cancer progression
KW - Cancer therapy
KW - Endothelial differentiation
KW - Metabolic remodeling
KW - Tumor microenvironment (TME)
UR - http://www.scopus.com/inward/record.url?scp=85081042577&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-34025-4_8
DO - 10.1007/978-3-030-34025-4_8
M3 - Chapter
C2 - 32130698
AN - SCOPUS:85081042577
T3 - Advances in Experimental Medicine and Biology
SP - 143
EP - 159
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -
